Concepta PLC Notice of Annual General Meeting (0429P)
05 Giugno 2020 - 8:00AM
UK Regulatory
TIDMCPT
RNS Number : 0429P
Concepta PLC
05 June 2020
Concepta PLC
("Concepta" or the "Company")
Notice of Annual General Meeting
Concepta PLC (AIM: CPT), the innovative UK personalised
healthcare company and developer of myLotus(R), the UK's most
accurate home-use fertility tracking and pregnancy self-testing
system, announces that the Notice of Annual General Meeting ("AGM")
and associated form of proxy will be sent to shareholders
today.
The Company's AGM will be held at 52, Ninian Road, Cardiff CF23
5EJ at 11.00am on Thursday 2 July 2020.
In the light of the Government's Stay at Home measures
("Measures") and its advice that non-essential travel and
gatherings should be avoided, the Board requests that no
shareholders should attend the meeting. Any shareholders (other
than the two shareholders referred to below) that do attend will be
refused entry. Only two shareholders will attend in person. These
shareholders will constitute the minimum quorum for the AGM to take
place under the Company's articles of association ("Articles") and
company law requirements.
The Company will provide a facility for shareholders to join the
AGM online or telephonically. In order to facilitate the process,
the Board would request that shareholders register for the meeting
before 5.00pm (BST) on Wednesday 1 July 2020. To register for
dial-in details please email Walbrook PR at concepta@walbrookpr.com
or call +44 (0)20 7933 8787.
Shareholders should note that only the usual and formal business
set out in the notice of AGM will be considered at the AGM. The
meeting will be conducted swiftly, with a short presentation by the
directors but no question and answer session. Accordingly,
shareholders wishing to vote on any of the matters of business are
urged to do so through completion of a proxy form, which can be
submitted to the Company ' s Registrar. Proxy forms should be
completed and returned in accordance with the instructions
thereon.
Although the Notes to the Notice of the AGM refer to
shareholders being able to appoint a proxy or proxies, the Company
would remind shareholders that, in light of the Measures, they will
not be allowed entry to the AGM. However, the Company does value
shareholder participation and values the votes of shareholders, so
it would encourage all shareholders to exercise their voting rights
BUT ONLY by appointing the chairman of the AGM to be their proxy.
Any proxy received appointing a person other than the chairman of
the AGM as the shareholder's proxy will be deemed to have appointed
the chairman of the AGM as that shareholder's proxy.
Any shareholder who has a question is invited to contact the
Company (by email to the Chairman of the Company, via Walbrook PR
at concepta@walbrookpr.com ) by 30 June 2020 and the Company will
post answers on its website at www.conceptaplc.com after 5.00pm
(BST) on Wednesday 1 July 2020.
The Annual Report and Accounts, Notice of AGM and associated
form of proxy are available on the Company's website at
www.conceptaplc.com .
Concepta plc www.conceptaplc.com
P enny McCormick , Chief Executive via Walbrook PR
Officer
Maddy Kennedy, Chief Financial
Officer
SPARK Advisory Partners Limited Tel: +44 (0)20 3368 3550
(NOMAD)
Neil Baldwin
Novum Securities (Broker) Tel: +44 (0)20 7399 9400
Colin Rowbury
Walbrook PR Ltd (Media & Investor Tel: +44 (0)20 7933 8780 or concepta@walbrookpr.com
Relations)
Paul McManus Mob: +44(0)7980 541 893
About Concepta PLC ( www.conceptaplc.com )
Concepta PLC is an AIM-quoted pioneering UK healthcare company
that has developed a proprietary product, myLotus(R), targeted at
the personalized mobile health market with a primary focus on
hormone testing and increasing a woman's chances of naturally
getting pregnant and to provide insight to unexplained
infertility.
myLotus(R) is currently the only consumer product which allows
both quantitative and qualitative home (self-test) test measurement
of a woman's personal luteinizing hormone (LH) during ovulation and
human chorionic gonadotropin (hCG) hormone level during pregnancy,
facilitating higher conception rates and early diagnosis of
fertility issues. The proposition of myLotus(R) is to empower women
to better understand their hormone levels and menstrual cycle and
help women conceive naturally by identifying their window of
fertility and optimal time for conception.
The Company has received CE-mark certification for myLotus(R)
and has launched its first product in the UK. The Company is
preparing plans to roll-out across the core EU countries in
2020.
myLotus(R) is expected to be beneficial to users who have been
unable to conceive after 6 months of trying. This highly motivated
target group of women won't typically be offered medical
intervention until after 12 months of unsuccessfully trying to
conceive, with IVF not usually offered until after two years of
trying to conceive. Research indicates couples start to take
positive action ahead of this time typically with little medical
support to help them do so.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NOAFZGGVMDKGGZZ
(END) Dow Jones Newswires
June 05, 2020 02:00 ET (06:00 GMT)
Grafico Azioni Myhealthchecked (LSE:MHC)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Myhealthchecked (LSE:MHC)
Storico
Da Apr 2023 a Apr 2024